RT journal article
T1 Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA)
A1 Pereyra-Rodriguez, José-Juan
A1 Poveda, J.L.
A1 Rivero, A.
A1 Serra Baldrich, E.
A1 Silvestre, J.F.
A1 Armario Hita, José Carlos
A1 Calleja, M.A.
A1 Carrascosa, J. M.
A1 Flórez, A.
A1 Herranz, P.
A1 Comellas, M.
A1 Ortiz de Frutos, F.J.
A2 Medicina
K1 Decision Making
K1 Decision Support Techniques
K1 Dermatitis, Atopic
K1 Humans
K1 atopic dermatitis
K1 clinical decision making
K1 clinical outcome
K1 conceptual framework
K1 dermatologist
K1 disease activity
K1 disease control
K1 disease severity
K1 drug cost;
K1 drug safety
K1 hospital pharmacist
K1 human
K1 incidence
K1 Letter
K1 multicriteria decision analysis
K1 pain
K1 patient-reported outcome
K1 pruritus
K1 publication
K1 quality of life
K1 sleep disorder
K1 atopic dermatitis
K1 decision making
K1 decision support system
AB Dear Editor,The increased understanding of atopic dermatitis (AD)pathophysiology has shed light on the underlying immuno-logical mechanisms and spurred the development of novel,more precisely targeted therapies.1 As new agents becomeavailable, assessing their added value is advisable. Yet thevalue of novel health interventions sometimes remainslargely unmeasured and inadequately understood. 2 Valueassessment is challenging since it involves assessing the ex-tent to which it meets current unmet needs. Therefore, it isnecessary to establish the most relevant health outcomesfrom different stakeholders' perspectives.The main goal of AD treatment is to establish and sus-tain disease control, allowing patients to be fully functionalin their lives. 3 Therefore, the value of novel treatmentsshould be assessed not only according to their effectivity intarget skin clearance but also improving patient-reportedoutcomes.
PB John Wiley and Sons Inc
SN 1468-3083
YR 2024
FD 2024
LK http://hdl.handle.net/10498/31506
UL http://hdl.handle.net/10498/31506
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 12-nov-2026